• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study.

出版信息

Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):9-10.

PMID:38445000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910368/
Abstract
摘要

相似文献

1
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：3期QUASAR诱导研究结果
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):9-10.
2
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.古塞单抗治疗中重度活动性溃疡性结肠炎患者：QUASAR 期 2b 诱导研究。
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
3
The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.古塞库单抗诱导治疗中重度活动性溃疡性结肠炎患者的疗效和安全性：2b期QUASAR研究第12周结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):12.
4
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗作为中度至重度活动性溃疡性结肠炎患者维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):8-9.
5
The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy.古塞库单抗诱导疗法对中度至重度活动性溃疡性结肠炎患者的疗效：QUASAR 2b期诱导治疗第12周时既往对先进疗法反应不足或不耐受患者的结果
Gastroenterol Hepatol (N Y). 2022 Nov;18(11 Suppl 3):12-13.
6
Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study.古塞库单抗诱导治疗对中度至重度活动性溃疡性结肠炎的早期症状改善：3期QUASAR研究结果
Gastroenterol Hepatol (N Y). 2023 Dec;19(12 Suppl 9):2-3.
7
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.古塞库单抗联合戈利木单抗与古塞库单抗或戈利木单抗单药治疗溃疡性结肠炎患者的疗效比较（VEGA）：一项随机、双盲、对照、2期概念验证试验
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1.
8
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
9
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.对接受8周诱导治疗有反应的中度至重度活动性溃疡性结肠炎患者进行乌帕替尼维持治疗的疗效和安全性（U-ACHIEVE维持治疗）：随机、安慰剂对照、双盲3期维持研究的总体结果
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9.
10
Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.古塞库单抗与戈利木单抗联合诱导治疗中度至重度活动性溃疡性结肠炎患者的疗效和安全性：一项2a期随机、双盲、活性对照、平行组、多中心概念验证研究第12周的结果
Gastroenterol Hepatol (N Y). 2022 Apr;18(4 Suppl 1):9-10.

引用本文的文献

1
When the First Advanced Therapy Fails.当首次先进治疗失败时。
Gastroenterol Hepatol (N Y). 2025 Mar;21(1 Suppl 1):9-11.
2
Horizon scanning: new and future therapies in the management of inflammatory bowel disease.前沿扫描：炎症性肠病管理中的新疗法与未来疗法
eGastroenterology. 2023 Oct 27;1(2):e100012. doi: 10.1136/egastro-2023-100012. eCollection 2023 Sep.
3
Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗诱导治疗第24周临床应答者中，古塞库单抗维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Dec;20(12 Suppl 10):2-3.
4
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.AGA 临床实践指南：中重度溃疡性结肠炎的药物治疗管理
Gastroenterology. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001.
5
The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study.古塞库单抗作为中度至重度活动性溃疡性结肠炎患者维持治疗的疗效和安全性：3期QUASAR维持研究结果
Gastroenterol Hepatol (N Y). 2024 Jul;20(7 Suppl 6):8-9.
6
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.炎症性肠病的现代先进疗法：实际考量与定位
Clin Gastroenterol Hepatol. 2025 Feb;23(3):454-468. doi: 10.1016/j.cgh.2024.06.050. Epub 2024 Aug 13.
7
Highlights in Ulcerative Colitis From Digestive Disease Week 2023: Commentary.2023年消化系统疾病周溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):13-16.

本文引用的文献

1
Emerging therapies for ulcerative colitis.溃疡性结肠炎的新兴疗法。
Expert Rev Clin Immunol. 2022 May;18(5):513-524. doi: 10.1080/1744666X.2022.2069562. Epub 2022 May 1.